|
1
|
Lu J, Steeg PS, Price JE, Krishnamurthy S,
Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, et
al: Breast cancer metastasis: Challenges and opportunities. Cancer
Res. 69:4951–4953. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O’Shaughnessy J: Extending survival with
chemotherapy in metastatic breast cancer. Oncologist. 10(Suppl 3):
S20–S29. 2005. View Article : Google Scholar
|
|
3
|
Friedl P and Wolf K: Tumour-cell invasion
and migration: Diversity and escape mechanisms. Nat Rev Cancer.
3:362–374. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsukita S and Yonemura S: ERM
(ezrin/radixin/moesin) family: From cytoskeleton to signal
transduction. Curr Opin Cell Biol. 9:70–75. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nestl A, Von Stein OD, Zatloukal K, Thies
WG, Herrlich P, Hofmann M and Sleeman JP: Gene expression patterns
associated with the metastatic phenotype in rodent and human
tumors. Cancer Res. 61:1569–1577. 2001.PubMed/NCBI
|
|
6
|
Yu H, Zhang Y, Ye L and Jiang WG: The FERM
family proteins in cancer invasion and metastasis. Front Biosci.
16:1536–1550. 2011. View
Article : Google Scholar
|
|
7
|
Yu Y, Khan J, Khanna C, Helman L, Meltzer
PS and Merlino G: Expression profiling identifies the cytoskeletal
organizer ezrin and the developmental homeoprotein Six-1 as key
metastatic regulators. Nat Med. 10:175–181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khanna C, Wan X, Bose S, Cassaday R, Olomu
O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The
membrane-cytoskeleton linker ezrin is necessary for osteosarcoma
metastasis. Nat Med. 10:182–186. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meng Y, Lu Z, Yu S, Zhang Q, Ma Y and Chen
J: Ezrin promotes invasion and metastasis of pancreatic cancer
cells. J Transl Med. 8:612010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang YK, Hong SW, Lee H and Kim WH:
Prognostic implications of ezrin expression in human hepatocellular
carcinoma. Mol Carcinog. 49:798–804. 2010.PubMed/NCBI
|
|
11
|
Saito S, Yamamoto H, Mukaisho K, Sato S,
Higo T, Hattori T, Yamamoto G and Sugihara H: Mechanisms underlying
cancer progression caused by ezrin overexpression in tongue
squamous cell carcinoma. PLoS One. 8:e548812013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gschwantler-Kaulich D, Natter C, Steurer
S, Walter I, Thomas A, Salama M and Singer CF: Increase in ezrin
expression from benign to malignant breast tumours. Cell Oncol.
36:485–491. 2013. View Article : Google Scholar
|
|
13
|
Halon A, Donizy P, Surowiak P and
Matkowski R: ERM/Rho protein expression in ductal breast cancer: A
15 year follow-up. Cell Oncol. 36:181–190. 2013. View Article : Google Scholar
|
|
14
|
Elliott BE, Meens JA, SenGupta SK, Louvard
D and Arpin M: The membrane cytoskeletal crosslinker ezrin is
required for metastasis of breast carcinoma cells. Breast Cancer
Res. 7:R365–R373. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y,
Liu P, Song A, Gang C, Han Z, et al: Ezrin silencing by small
hairpin RNA reverses metastatic behaviors of human breast cancer
cells. Cancer Lett. 261:55–63. 2008. View Article : Google Scholar
|
|
16
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jeanes A, Gottardi CJ and Yap AS:
Cadherins and cancer: How does cadherin dysfunction promote tumor
progression? Oncogene. 27:6920–6929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Foschini MP, Leonardi E, Eusebi LH,
Farnedi A, Poli T, Tarsitano A, Cocchi R, Marchetti C, Gentile L,
Sesenna E, et al: Podoplanin and E-cadherin expression in
preoperative incisional biopsies of oral squamous cell carcinoma is
related to lymph node metastases. Int J Surg Pathol. 21:133–141.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang C, Jiang K, Kang X, Gao D, Sun C, Li
Y, Sun L, Zhang S, Liu X, Wu W, et al: Tumor-derived secretory
clusterin induces epithelial-mesenchymal transition and facilitates
hepatocellular carcinoma metastasis. Int J Biochem Cell Biol.
44:2308–2320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang WS, Yu SL, Yang XS, Chang SD and Hou
JQ: Expression and significance of twist and E-cadherin in ovarian
cancer tissues. Asian Pac J Cancer Prev. 14:669–672. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stanczak A, Stec R, Bodnar L, Olszewski W,
Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M and
Lamparska-Przybysz M: Prognostic significance of Wnt-1, β-catenin
and E-cadherin expression in advanced colorectal carcinoma. Pathol
Oncol Res. 17:955–963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rakha EA, Patel A, Powe DG, Benhasouna A,
Green AR, Lambros MB, Reis-Filho JS and Ellis IO: Clinical and
biological significance of E-cadherin protein expression in
invasive lobular carcinoma of the breast. Am J Surg Pathol.
34:1472–1479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oka H, Shiozaki H, Kobayashi K, Inoue M,
Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S,
Takeichi M, et al: Expression of E-cadherin cell adhesion molecules
in human breast cancer tissues and its relationship to metastasis.
Cancer Res. 53:1696–1701. 1993.PubMed/NCBI
|
|
24
|
Chen MJ, Gao XJ, Xu LN, Liu TF, Liu XH and
Liu LX: Ezrin is required for epithelial-mesenchymal transition
induced by TGF-β1 in A549 cells. Int J Oncol. 45:1515–1522.
2014.PubMed/NCBI
|
|
25
|
Fang Y, Wei J, Cao J, Zhao H, Liao B, Qiu
S, Wang D, Luo J and Chen W: Protein expression of ZEB2 in renal
cell carcinoma and its prognostic significance in patient survival.
PLoS One. 8:e625582013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ,
Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, et al: Overexpression
of EIF5A2 promotes colorectal carcinoma cell aggressiveness by
upregulating MTA1 through C-myc to induce
epithelial-mesenchymaltransition. Gut. 61:562–575. 2012. View Article : Google Scholar
|
|
27
|
Sarrió D, Rodríguez-Pinilla SM, Dotor A,
Calero F, Hardisson D and Palacios J: Abnormal ezrin localization
is associated with clinicopathological features in invasive breast
carcinomas. Breast Cancer Res Treat. 98:71–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pujuguet P, Del Maestro L, Gautreau A,
Louvard D and Arpin M: Ezrin regulates E-cadherin-dependent
adherens junction assembly through Rac1 activation. Mol Biol Cell.
14:2181–2191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Siitonen SM, Kononen JT, Helin HJ, Rantala
IS, Holli KA and Isola JJ: Reduced E-cadherin expression is
associated with invasiveness and unfavorable prognosis in breast
cancer. Am J Clin Pathol. 105:394–402. 1996.PubMed/NCBI
|
|
30
|
Yoshida R, Kimura N, Harada Y and Ohuchi
N: The loss of E-cadherin, α- and β-catenin expression is
associated with metastasis and poor prognosis in invasive breast
cancer. Int J Oncol. 18:513–520. 2001.PubMed/NCBI
|
|
31
|
Brzozowska A, Sodolski T, Duma D,
Mazurkiewicz T and Mazurkiewicz M: Evaluation of prognostic
parameters of E-cadherin status in breast cancer treatment. Ann
Agric Environ Med. 19:541–546. 2012.PubMed/NCBI
|
|
32
|
Kowalski PJ, Rubin MA and Kleer CG:
E-cadherin expression in primary carcinomas of the breast and its
distant metastases. Breast Cancer Res. 5:R217–R222. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Y, Zhao Y, Jiang G, Zhang X, Zhao H,
Wu J, Xu K and Wang E: Impact of p120-catenin isoforms 1A and 3A on
epithelial mesenchymal transition of lung cancer cells expressing
E-cadherin in different subcellular locations. PLoS One.
9:e880642014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lapyckyj L, Castillo LF, Matos ML,
Gabrielli NM, Lüthy IA and Vazquez-Levin MH: Expression analysis of
epithelial cadherin and related proteins in IBH-6 and IBH-4 human
breast cancer cell lines. J Cell Physiol. 222:596–605. 2010.
|
